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 New contraceptive methods provide greater choice in terms of effectiveness, 
management of side-effects, convenience and frequency of administration and 
flexibility, but make the decisions about contraception more complex. There are 
limited data on the factors that determine women’s choices among these alternatives, 
to inform providers about the factors which are most important to women, or to 
predict uptake of new products. This paper reports on a choice experiment designed to 
elicit women’s preferences in relation to prescribed contraception and to forecast the 
impact of the introduction of two new products into the Australian market.  A 
generalized multinomial logit model is estimated and used in the simulation exercise. 
The model forecasts that the hormonal patch would be well received among women, 
achieving a greater market share than current non-pill products, but the vaginal ring 
would have limited appeal. 
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The range and complexity of contraceptive choices available in developed countries 
has increased dramatically, with implications for consumers and health care providers. 
While the combined contraceptive pill has been the dominant method of contraception 
for many decades, in the last five years there has been rapid development of new 
formulations of the pill and new long-acting methods such as hormonal IUDs, 
implants, intra-vaginal methods and hormonal patches. These new methods provide 
women with much greater contraceptive choice in terms of effectiveness, management 
of side-effects, convenience and frequency of administration and flexibility, but make 
the decisions about contraception more complex. The availability of new products 
also requires providers to determine what information is of most interest and 
relevance to women to help them make decisions in relation to contraception.  
 
This study investigates factors which influence a woman’s choice of method of 
contraception. The study uses discrete choice experiment methods to quantify the 
trade-offs that women make in assessing different contraceptive alternatives, to 
provide information about how they choose under different circumstances, and to 
predict uptake of contraceptive alternatives new to the market. Previous research has 
used choice experiment methods to investigate contraceptive choices. Seston et al 
(2007) use a choice experiment to investigate trade-offs in relation to emergency 
contraception, focussing on attributes such as wait time, staff attitude and opening 
hours. However the trade-offs in relation to planned contraception are quite different. 
Terris-Prestholt et al (2009) have investigated trade-offs in relation to prevention of 
sexually transmitted diseases, prevention of pregnancy and cost in different barrier 
methods of contraception for women in South Africa. Delavande (2008) estimates 
willingness to pay for a hypothetical method of contraception that is 100% effective. 
A key focus of the current study is the prediction of uptake of new products in the 
planned contraceptive setting, as well as providing information that will be useful to 
providers in giving relevant advice and information to women about the 
characteristics of new and existing products. The focus on new products is a key 
motivation for using a discrete choice experiment method. Such methods are of 
particular use when there are limited data from actual market transactions as will be 




The complexity of prescribed contraceptive methods available and the existence of a 
complex range of “outside” options present particular design challenges not faced in 
typical discrete choice experiments. The choice experiment described in this paper 
incorporates eight alternative products, using seven attributes to describe these 
products. Some attributes, such as frequency of administration, have levels that are 
specific to only some of the products, whereas the levels of other attributes are 
common across all products. This presents specific challenges in developing a near-
optimal design, in terms of statistical efficiency, while still satisfying requirements of 
respondent efficiency. The DCE was constructed using a modification of a popular 
construction strategy, variously called simultaneous option generation or the LMA 
approach, and was tested in simulation studies to confirm that it could successfully 
recover a range of assumed prior parameter values.  
 
In terms of estimation, the need to predict new product demand requires a model that 
allows for flexible substitution patterns across very different alternatives. Random 
parameter specifications, such as mixed logit (MXL), are very popular in choice 
modelling applications partly because they do provide a means of capturing more 
flexible variance-covariance structures for the unobservables in choice models and 
hence avoid problems associated with independence of irrelevant alternatives (IIA). 
However, they neglect another potentially important aspect of heterogeneity 
associated with variations in scale. This study uses the generalized multinomial logit 
(G-MNL) framework recently developed in Fiebig, Keane, Louviere and Wasi (2010). 
Their work highlights the empirical importance of accommodating this extra 
dimension of heterogeneity over and above the flexibility provided by standard MXL 
model specifications. 
 
In broad methodological terms, this paper illustrates how the methods for designing 
and analysing choice experiments can be adapted to more complex choice problems. 
This has important implications for the application of choice experiments in health 
economics, where simplification of choice contexts and neglect of important sources 





2. What is known about contraceptive choices? 
Approximately 56 per cent of all Australian women aged 18 to 49 years use some 
form of contraception (National Health Survey, 2001 collected by the Australian 
Bureau of Statistics (ABS)). Since its introduction in 1961, the oral contraceptive pill 
has been the most commonly used method of contraception. New formulations of the 
pill including the progestogen only pill (mini pill) and lower dose formulations of the 
combined pill that reduce unwanted side-effects have increased its popularity.  Use of 
the contraceptive pill ranges from almost 70 per cent for 18 to 24 year olds to about 
41 per cent amongst 45 to 49 years olds (National Health Survey, 2001). Over 75 per 
cent of women aged 18 to 44 years were reported to have ever used the contraceptive 
pill, with half of those being under 20 years of age (Yusuf and Siedlecky, 2007).  
 
The proportion of women using other types of contraception such as the IUD, the 
diaphragm and the injection is generally lower. One reason may be lower awareness 
and availability of information about these alternative contraceptive methods. There 
are also differences in patterns of contraceptive use among some socio-demographic 
groups. The language spoken at home and the woman’s level of schooling are 
significant factors influencing contraceptive choices (Yusuf and Siedlecky, 2007). 
Most studies on contraceptive choice model the relationship between contraceptive 
choice and age. However, there is evidence that life stage, rather than age, drives 
contraceptive decisions (Gray and McDonald, 2007). 
 
In the past decade there have been considerable developments in the contraceptive 
market, leading to the introduction of a wider array of oral contraception formulations, 
as well as newer methods of contraception. In particular, there have been 
developments of new long-acting methods such as hormonal Intra-Uterine Devices 
and implants, injections, dermal patches and vaginal rings.  
 
Acceptability of new methods depends on familiarity with them, as demonstrated by 
results from trials of the vaginal ring in Europe and North America (Novák et al., 
2002). At the start of the trial in which women used the vaginal ring, almost 66 per 
cent of women indicated the pill was the best perceived method of contraception, but 
after 13 months of using the ring, 81 per cent reported that the ring was the best 
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perceived method. Gilliam et al (2007) found that a much larger percentage of North 
American college students expressed willingness to use the transdermal patch and 
vaginal ring than were actually using it, despite their availability. There was a 
negative correlation between willingness to use new methods and current use of the 
oral pill. This reluctance to switch from the pill may explain the slower uptake of 
newer contraceptive options. 
 
The availability of so many different contraceptive choices poses challenges for GPs 
in providing the balanced and comprehensive information necessary for women to be 
able to make a fully informed choice.  More information about the factors that 
influence women’s choices can assist GPs in providing this information. While 
market or revealed preference data are available that characterize the types of 
contraceptive choices women are currently making (Yusuf and Siedlecky (2007) and 
Gray and McDonald (2007)), these data provide little or no detailed information about 
what is driving these choices. In particular, there would only be limited variability in 
key product characteristics across different contraceptives and it is this type of 
information that is required in order to predict how women will respond to new 





3. Development of the choice experiment 
3.1 Overview of the experiment 
Stated preference data from a discrete choice experiment (DCE) are used to evaluate 
women’s preferences for attributes of alternative contraceptive products. The choice 
experiment was designed to reflect realistically the exchange of information and the 
choices that are likely to be made in a typical consultation between a woman and her 
GP in relation to contraception. The complexity of prescribed contraceptive methods 
available and the existence of a complex range of “outside” options present particular 
design challenges not faced in typical discrete choice experiments. The aim was to 
reflect the context of the consultation in the attributes of the experiment and present 
the range of prescribed contraceptive products that might be discussed without leading 
to cognitive overload, and allow for women to choose a realistic outside option (stay 
with her existing method). The experiment includes contextual factors and a range of 
contraceptive products, and varies the attributes of the products within a realistic 
range. 
 
3.2 Development of attributes 
Attributes were selected from a review of the literature and in discussion with clinical 
experts in the field of family planning and a series of focus groups with women 
generally, young women specifically and GPs. The final set of attributes consisted of 
a labelled product attribute (8 levels) and 7 other attributes (effect on acne, effect on 
weight, frequency of administration, contraceptive effectiveness, doctor’s 
recommendation, effect on periods and cost). Attribute levels were selected to include 
a range of realistic values, either actual or hypothetical. The levels of the attributes 
“frequency of administration” and “contraceptive effectiveness” were nested within 
subsets of products to allow each product to be described in terms of plausible levels 
of these two attributes. This ensured that all of the options that were eventually shown 
to respondents were realistic, even if some were hypothetical. See Table 1 for a full 
list of attributes and levels. 
 
3.3 Design of the Choice Experiment 
Presenting all eight products in each choice set was considered to be both cognitively 
demanding, and unlikely to reflect the real choice sets women would be offered at a 
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consultation. However, given that the product category was one with which 
respondents were familiar, choice sets of size three were considered to be feasible, 
and realistic. In another component of our research, we have asked GPs how many 
products they would discuss with different patients and find that the median and 
modal number of products discussed is 3. Each choice task consisted of choosing both 
the best and the worst from a set of three options and each respondent completed 32 
such tasks.  
 
Usually if there are products described by attributes with different levels then each 
choice set contains one option of each product. The particular choice sets to use are 
determined by constructing the three options to be presented in each choice set at the 
same time. This was achieved by constructing a resolution 3 fraction of the 
appropriate factorial design. As well as having the attributes associated with each 
product, we have extended this idea further and included an additional attribute to 
indicate the product that should be included for each of the three options in each 
choice set. Each product is described by eight attributes. As the first has 8 levels, the 
second has 3 levels and so on we choose the first option as a combination from a 
(8×3×5×4×4×8×3×3) factorial. This is true for each of the other options in each 
choice set. Thus we have found the choice sets by constructing a resolution 3 fraction 
of an (8×3×5×4×4×8×3×3) × (8×3×5×4×4×8×3×3) × (8×3×5×4×4×8×3×3) factorial, 
where the brackets indicate the three options and of course play no substantive role in 
determining the fraction. Thus we are using a modification of the LMA construction 
technique, where we have M=3 options in each choice set and A=8 attributes for each 
option, but the attributes do not all have L levels. 
 
Indeed from the mathematical perspective the order of the attribute levels is 
immaterial and thus we want to find a resolution 3 fraction of the 86×53×46×39 
complete factorial. If we work directly with these values and insist on equal occurence 
of pairs of attribute levels for all pairs of attributes (to ensure a diagonal covariance 
matrix), then the smallest design would have N = 9×25×64 = 14400 choice sets which 
was not a tractable number. Instead we decided that we would find a resolution 3 
fraction of a 89×415 complete factorial and then collapse three 8-level attributes to 
obtain the 5-level attributes and collapse nine 4-level attributes to obtain the 3-level 
attributes. The initial design that we used was the 26×412×810×16 with 128 treatment 
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combinations given in Kuhfeld (2006). We then replaced the 16 level attribute by 
three 4-level attributes to give a 26×415×810. We then removed one of the 8-level 
attributes and all of the 2-level attributes. The most common levels were chosen to 
have higher replication to increase the plausibility of options.  These 128 choice sets 
were blocked into 4 versions each with 32 choice sets. Respondents were randomly 
allocated to one of these versions. Although the theoretical covariance matrix from 
such a collapsing is known to be non-diagonal (see Street and Burgess 2007 for a 
comprehensive discussion), we performed simulation studies that confirmed that we 
were able to accurately recover a range of assumed prior values of the parameters 
using this design. 
 
One consequence of this method of construction is that in some choice sets a product 
will appear twice. This not only reflects the reality of a consultation (in which two 
different brands of a product might be presented), but from a design perspective is 
perfectly acceptable, as a fraction was chosen in which the levels of the attributes for 
the two occurrences were not the same and so two different items were available in 
the choice set. In addition, in the DCE that we constructed the generic attributes were 
not in fact nested within product (although as described above the construction 
method might have made it appear that they were) and so the main effects of the 
generic attributes could be, and indeed were, fitted across the products. Simulation 
studies confirmed that the two-factor interaction effects of all of the attributes with 
products could be estimated if desired and a range of assumed prior values could be 
recovered. 
 
3.4 Choice task 
As noted above, each choice set presented three product options of which respondents 
were asked to choose the best and the worst based on the described attributes of each 
option. Respondents were then asked whether they would choose the selected best 
option over their current method of contraception. Figure 1 depicts a representative 
example of a choice set. We restrict our attention to the initial decision to choose the 
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best option amongst the three alternatives. Analysis of the other choice data will be 
pursued in later work1.   
 
The experiment had labelled options with the 8 levels of product as the option labels. 
Since there were only 3 options per choice set, not all products were available in each 
choice task. Therefore a woman’s preference for a particular product could only be 
expressed in those choice sets where the preferred product was one of the three 
options.  
 
3.5 Recruitment and data collection  
The DCE was completed on-line. Respondents were recruited from an on-line panel 
by a market research company. Women aged 18-49 years, currently using or planning 
to use contraception to prevent pregnancy in the next 5 years were eligible to 
participate.  
                                                 
1  The experimental design was repeated over three information conditions and a woman was 
randomised to complete only one of these conditions. The conditions were (a) basic information 
condition: women in this arm of the DCE were given information about the products and attributes to 
assist them with the experiment without any particular emphasis on any product. (b) A “scare” 
condition: as well as the basic information on each product, women were shown a short article on the 
risks associated with the use of the contraceptive pill before completing the DCE. (c) A “promotion” 
condition: as well as the basic information on each product, women were shown a short promotional 
article on the features of the patch and vaginal ring before completing the DCE. In this paper we report 




4. Econometric analysis 
4.1 The Generalized Multinomial Logit Model 
The analysis of the choice data relies on a random utility model where the utility that 
woman i derives from choosing alternative j in choice scenario s is given by 
 
SsJjniXU isjisjisj ,...,1;,...,1;,...,1;)1( ===+′= εβ  
 
where Xisj  is a K×1 vector of explanatory variables and β is a conformable vector of 
coefficients. Assuming the disturbance terms εisj to be identically and independently 
distributed as extreme value, the standard multinomial logit (MNL) specification 
results.  Simplicity of estimation and interpretation are among the main advantages of 
this model but these come at the cost of some restrictive assumptions that are clearly 
unrealistic in our choice context.  
 
Random parameter specifications such as mixed logit (MXL) have become very 
popular in choice modelling applications; see for example Revelt and Train (1998), 
Brownstone and Train (1999), Hall et al (2006) and Hole (2008). They provide an 
appealing and tractable way to extend basic binary and multinomial choice models, 
and the development of widely available software has made MXL an attractive 
estimation approach for empirical research. Random parameter choice models have 
two compelling justifications. First, preference heterogeneity which is pervasive in 
modelling individual choice behaviour is quite naturally formulated in terms of 
random parameter models. Second, these specifications provide a potential means of 
capturing more flexible variance-covariance structures for the unobservables in choice 
models and hence avoid problems associated with independence of irrelevant 
alternatives (IIA). This second justification is especially relevant in the current 
analysis where predicting new product demand is a key component of our analysis. 
Such an analysis requires a model that allows for flexible substitution patterns across 
very different alternatives.  
 
Here we adopt the generalized multinomial logit (G-MNL) framework recently 
developed in Fiebig, Keane, Louviere and Wasi (2010). This framework includes 
standard MXL specifications as special cases but additionally allows for individual 
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scale heterogeneity. The work of Fiebig, Keane, Louviere and Wasi (2010) highlight 
the empirical importance of accommodating this extra dimension of heterogeneity.   
 
In order to motivate the G-MNL model, first extend (1) by allowing for scale 
heterogeneity, that is rather than assuming εisj has a fixed scale (or variance), we allow 
it to vary across respondents to obtain:  
 
SsJjniXU iisjisjisj ,...,1;,...,1;,...,1;/)2( ===+′= σεβ  
 
where the scale has been denoted by the scalar σi. Now rewrite (2) to obtain an 
equivalent formulation: 
 
SsJjniXU isjiisjisj ,...,1;,...,1;,...,1;)()3( ===+′= εβσ . 
 
The scale heterogeneity model is observationally equivalent to a particular type of 
heterogeneity in the utility weights, an observation that has led Louviere et al (2008) 
to be critical of the standard MXL model. At the very least one should be aware that 
apparent preference heterogeneity discovered through a random parameter MXL 
specification might be better modelled as the result of scale heterogeneity.  
 
The G-MNL model accommodates both sources of heterogeneity. For example, taste 
heterogeneity or “residual” taste heterogeneity can be introduced by extending (3) to 
obtain: 
 
SsJjniXU isjiiisjisj ,...,1;,...,1;,...,1;)()4( ===++′= εηβσ  
 
whereby the so-called G-MNL-I model results. The full G-MNL model of Fiebig, 
Keane, Louviere and Wasi (2010) provides flexibility in how scale and taste 
heterogeneity are combined. Implementation within this general framework still 
requires answers to important specification questions related to how scale 
heterogeneity is captured, what other parameters are assumed random, what 
distributions to choose to represent taste heterogeneity and whether to allow 




4.2 Model specification  
One attraction of a model of scale heterogeneity, as is specified below, is a 
considerable amount of flexibility with the addition of only one parameter. Because σi 
is required to be positive we specify an exponential transformation given by: 
 













The additional parameter τ provides a measure of scale heterogeneity. A τ of zero 
would imply that the G-MNL model reduces to a standard MXL specification.  
 
In its most general form, the G-MNL model can involve a large number of parameters. 
For example, with the number of attributes in our study, allowing all their coefficients 
to be random and correlated would require the estimation of over 600 parameters. A 
more parsimonious specification is clearly required. As our other primary concern is 
capturing flexible substitution patterns, alternative specific constants (ASCs), that 
here represent the different contraceptive products, are assumed to be random and 
correlated. Fiebig, Keane, Louviere and Wasi (2010) argue that ASCs are 
fundamentally different from most observed attributes and as such recommend that 
they not be subject to scaling. This specification, together with scale heterogeneity as 
defined in (5) applied to other attributes, are combined to form our base model: 
 
SsJjniXzU isjiisjijjijisj ,...,1;,...,1;,...,1;)()()6( 00 ===+′++′+= εβσηγβ  
 
where X is now interpreted as including observed attributes exclusive of ASCs and we 
have allowed for interactions between the ASCs and individual specific characteristics. 
In what follows we simply refer to (6) as the G-MNL model.  
 
In this framework there is flexibility in the choice of the distribution of the vector of 
ASC random components η0i. Here a multivariate normal distribution with zero mean 
and covariance matrix Σ is assumed. Assuming normality seems sensible because 
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there are no strong priors on the signs of these coefficients and importantly allowing 
correlation introduces error dependence across the alternatives in each choice 
situation. Also, assuming random effects to be individual specific induces correlation 
across choice situations, accounting for the dependence structure in unobserved utility 
among the repeated choices of a woman which comes from the panel structure of the 
data. This would be expected, since the same unobserved factors affect a specific 
respondent, to a certain degree, over the repeated choices. This correlation is not 
perfect because of the presence of the independent extreme value terms εisj.  
 
Estimation by maximum simulated likelihood (MSL) is undertaken using a program 
kindly provided by Dr Nada Wasi. All estimation results reported below were 
generated using 1000 Halton draws to simulate the likelihood functions to be 




5.1 Data  
In total, 700 eligible women entered the study and 528 completed the survey, giving a 
completion rate of 75%. Of those that completed the survey 173 were allocated to the 
basic information condition but two of these respondents were subsequently dropped 
because of missing covariate information. Current contraceptive use and socio-
demographic variables for the entire sample and for the 171 respondents assigned to 
the basic information sample are summarized in Table 2.  
 
The mean age of the respondents in the basic information condition was 30 years. The 
median household income was over $67,000 pa and 44% were in full-time 
employment. Sixty-seven percent were currently using some form of contraception, 
58% were currently using the pill, 54% were using condoms (50% were using pill 
only and 24% condoms only). Twelve percent of women used a non-oral prescribed 
method of contraception, 4% were currently using DepoProvera injection and 4.7% 
were using an implant. Seventeen percent of women had been advised against the use 
of a particular method of contraception for health reasons and 9.8% had been advised 




When compared with the sub-population of Australian women aged 18-49 the survey 
sample was somewhat younger than the sub-population, with 83% of women in the 
sample in the age group 18 to 39 years, compared with 67% in the sub-population 
(ABS, 2006). The study only included women who were either using or were likely to 
use contraception in the near future, thus excluding a larger proportion of women in 
the older age group. The women’s current use of contraceptive methods was typical of 
other samples of Australian women; compare Tables 2 and 3.  
 
5.2 Estimation results  
In the models estimated, the base model given by (6) includes the women’s income 
and their current contraceptive method as covariates interacted with each of the 
product effects. In the case of current method, women were classified into three 
mutually exclusive and exhaustive groups: a base group who do not use any 
prescribed method (i.e. condoms only, emergency, other non-prescribed or no 
method), those who only use the pill and those who use a prescribed method other 
than the pill. As is common in studies similar to this, the addition of random 
individual-specific effects renders insignificant most effects associated with socio-
demographic characteristics. So while much more detailed information is available for 
these women, these effects cannot be precisely estimated if added to our model and 
we retain only this small set of covariates. The base model also includes necessary 
normalizations whereby the ASC for the IUD and associated interactions with socio-
demographic characteristics are set to zero.    
 
Table 4 provides a comparison of fit across several different models. Starting with a 
basic MNL model, the separate addition of either correlated random ASCs (MXL) or 
scale heterogeneity (G-MNL-A) leads to a dramatic improvement in fit.  Recall that 
the latter comes at the expense of only a single extra parameter but even after making 
degrees of freedom adjustments using either AIC or BIC, MXL fits better than G-
MNL-A.  
 
G-MNL-B and G-MNL-C incorporate both sources of heterogeneity but the former 
does not allow for correlated product effects. Our expectation was that these effects 
would need to be correlated in order to capture differential substitution patterns and 
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here we find confirmation, at least in terms of fit. Thus G-MNL-C is our preferred 
model providing the best fit amongst the models considered as measured by AIC, BIC 
or Pseudo-R2.  
 
In these data it seems that both scale and preference heterogeneity are present. To 
explore further the relative contributions of these two sources of heterogeneity a 
comparison of model fit is provided in terms of each woman’s log-likelihood 
contribution. In Figure 2, these contributions for MXL, G-MNL-A and G-MNL-C are 
overlayed, ordered by their contribution according to G-MNL-C.  As in a similar 
figure provided in Fiebig, Keane, Louviere and Wasi (2010), there appear to be three 
distinct segments. In the left most segment of the figure, where G-MNL-C fits the 
data best, G-MNL-C dominates both MXL and G-MNL-A and often by a substantial 
margin. In the middle section MXL and G-MNL-C are somewhat comparable in terms 
of fit. But the performance of G-MNL-A is more variable in this middle section; 
sometimes it does well compared to G-MNL-C but often it does very poorly.  In the 
right most segment, where the relative fit of G-MNL-C is poorest, G-MNL-C is again 
seen to dominate MXL. However, in this last segment G-MNL-A does well, 
dominating MXL and often being superior to G-MNL-C. 
 
These results indicate that scale heterogeneity better enables us to model extremes of 
behaviour. This is most pronounced in the last segment where choice behaviour is 
highly random and women’s choices are little affected by attribute values. In the first 
segment adding scale heterogeneity can often dramatically improve the performance 
of MXL. However, scale heterogeneity is clearly not the entire story and for the 
majority of the sample scale heterogeneity alone does not provide a good fit of 
individual choice behaviour. As might be expected for this particular choice problem, 
scale heterogeneity is important but preference heterogeneity is relatively more 
important for explaining behaviour over the entire sample of women.  
 
A full set of estimated parameters for the preferred G-MNL-C model are provided in 
Table 5. The estimated value of τ in this model is 0.781 with an estimated standard 
error of 0.085. Thus a Wald test indicates that τ is significantly different from zero 
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and further confirms the need to account for scale heterogeneity even after allowing 
for correlated random product effects.   
 
There are two key inferences to be drawn from the estimated means and standard 
deviations associated with the random product effects. First, all of the estimated mean 
product coefficients are positive except for the ring but only the effect for the 
injection is significantly different from zero at the 5% level. These coefficients need 
to be interpreted relative to the base product choice that was the IUD. This implies 
that after controlling for attribute differences, on average, there is little in the way of 
additional perceived product characteristics that lead women to prefer these products 
when compared to an IUD.  
 
Because current method and income has been interacted with the product ASCs, these 
inferences about mean effects relate to the base case of no prescribed method and no 
income. But while there are some distinct patterns in how the estimated product 
effects vary with the covariates, none of these individual effects are significant at the 
5% level.   
 
These are comparisons of average effects. The second key inference comes from 
considering the estimated standard deviations associated with the random product 
effects where our results suggest considerable variation around these mean tendencies. 
All estimated product effect standard deviations are large relative to their respective 
estimated means coefficients and all except that associated with the hormonal IUD are 
precisely estimated.  
 
In order to facilitate interpretation of the estimates associated with the remaining 
attributes, Figure 3 provides estimates of marginal willingness to pay (MWTP) 
calculated by dividing the attribute coefficient estimates by the estimated price 
coefficient, with the resultant ratios converted back into (Australian) dollars. 
Comparisons are easily made across different attributes as they represent, in dollar 
terms, the amount women are willing to trade off different attribute levels relative to 
the base level. To enhance comparability across attributes, the bases for the frequency 
attributes for injection, patch and ring and IUD implant were changed from the lowest 
to the highest period; so that the most preferred level is now the base for all attributes. 
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Note that none of the small negative estimates that appear in Figure 3 are associated 
with estimated coefficients that were precisely estimated. 
 
Recall from Table 1 that attributes have varying numbers of levels. Also note that 
there is nesting within the attributes “effect on bleeding” and “effect on weight” and 
hence for these two attributes the estimates of MWTP are broken up into like blocks. 
For the bleeding attribute, irregular bleeding and heavy and light periods with 
different pain levels are each compared to the common base of no period. Similarly 
different levels of weight gain and loss are compared to the common base of no effect 
on weight.   
 
It is clear that women are very concerned about bleeding and period pain.  Compared 
to the base level of no period, the estimates indicate women are prepared to pay a 
substantial amount to avoid irregular bleeding and heavy periods associated with any 
level of pain.  This is also the situation when a light period is combined with increased 
pain but women are not concerned about a light period with either less or no change in 
pain. In terms of other side effects, women want to avoid worsening acne and any 
weight gain but they place little value on improving acne or losing weight. 
 
Doctor recommendations also have a substantial impact on women’s choices. The 
difference between a positive recommendation (the base) and a negative 
recommendation has the second highest MWTP of $41. 
 
As noted earlier, effectiveness and frequency were defined differently for different 
products. Women were willing to pay substantial amounts to avoid the declining 
effectiveness of the pill, patch and ring defined as chance of pregnancy over 12 
months going from the base of 1 in 100 to 5 in 100 to 10 in 100 They were willing to 
pay similar amounts for avoiding declining effectiveness of the IUD, implant and 
injection going from 1 in 1000 to 1 in 500 and then to 1 in 100.  
 
Relative to effectiveness, there was more variation across product groups in terms of 
frequency of administration. For the IUD and implant, there was almost no difference 
in terms of MWTP between administration every one, three or years.  Women were 
willing to pay to avoid more frequent administration of the injection, patch and ring 
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but were indifferent between one and three months compared to the base of six 
months. For the pill women were willing to pay to avoid having to take the pill at 
particular times but were indifferent between taking it at the same time or within a 




These estimation results can now be used to predict the market share potentially 
captured by the new products, the hormonal skin patch and hormonal vaginal ring, if 
they were introduced into the current Australian market. Note that the current market 
is interpreted to be at the time of the survey which was conducted in 2007. Since this 
time, the ring has actually been introduced into the Australian market.     
 
6.1 Calibration  
The method described by Train (2003) was used to implement the simulations. First 
an out of sample data set was created that included the sub-set of products on the 
Australian market at the time of the survey. This subset contained the six products: 
combined pill, the minipill, the implant, the injection, the hormonal IUD and the IUD. 
The attribute levels for each of these products were set at the levels that most 
realistically describe that product and the covariates were set at their sample means. 
Estimates from the G-MNL-C model were used to simulate the predicted probabilities 
of the current set of products. This provides a predicted market share distribution that 
will not necessarily reflect the actual distribution of market shares for these products 
in Australia. Therefore using the method described by Train (2003) we recalibrated 
the product coefficients for the current product set so that the predicted probabilities 
estimated from the model more closely reflected the actual market share for each 
product currently available in Australia. The coefficients for the new products 
(vaginal ring and hormonal patch) were not constrained in the calibrated model. The 
distribution of contraceptive products that were currently being used by women in 
2005 according to the HILDA study (Gray and McDonald 2007) was selected as the 




The recalibration was an iterative process. The ratio of the predicted market share 
from the model to the actual market share from HILDA was used to recalibrate the 
product coefficients in the G-MNL-C according to: 
 
)ˆ/ln( 001 jjjj SS+=αα  
 
where: 
 Sj = actual market share in the forecast population  
0ˆ
jS  is the predicted market share from the model 
0




jα  is the new constant for product j to be fitted as a constraint in the next model. 
 
The model with the new product effects produced a new predicted share which was 
compared with the actual market share and new estimates were calculated for the 
products and the predictions were run again. This process was repeated until a set of 
estimated product effects was fitted that resulted in a predicted market share that 
approximated the actual market share. The outcomes of this process are provided in 
Table 6. Calibration raised the market share of the oral products from 46% to 74%, 
making it much closer to the population estimate of 82%. 
 
Once the model had been calibrated so that the predicted probabilities of the current 
product set reflected actual market share, the model was used to predict the 
probabilities of the full product set including the patch and vaginal ring to simulate 
the changes in market share with the introduction of new products. Again the 
attributes for the new products were set at realistic values. The out of sample 
probability estimates were simulated from 200 Halton draws. 
 
6.2 Simulation results 
The graph in Figure 4 depicts the market shares for each contraceptive product under 
four alternative scenarios. The current situation is that predicted by the calibrated 
model for the six existing products. The other three scenarios represent the predicted 
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market shares if the hormonal patch and vaginal ring were introduced together or 
separately into the current Australian market.  
 
The model predicts that the hormonal patch would achieve around 14% share of the 
market, whether introduced alone or with the vaginal ring. Relatively more of the 
share for the patch would come from the oral pill products, relatively less from the 
injection and the implant and the market for the Hormonal IUD and IUD would be 
relatively unaffected. The model predicts that the vaginal ring would capture 
approximately 3% of the current market share, in this case drawing more equally from 
other product shares. This market share for the ring is not sensitive to whether it is 
introduced alone or in conjunction with the patch. Together these results indicate that 
the patch and the ring appeal to somewhat different sectors of the market since 
introducing them together did not appreciably affect their separate market shares.  
 
The relative lack of appeal of the ring suggests some further simulations in order to 
determine the impact of making the ring a more attractive option. Two possible 
situations are considered: (i) the introduction of the ring together with a promotional 
program which is implemented in the simulation by specifying a recommendation for 
the ring by the GP; and (ii) allowing a price discount for the ring consistent with the 
product being subsidized under Australia’s Pharmaceutical Benefits Scheme. All 
other attribute levels remain the same as the initial simulation and the new results are 
compared to a base case from Figure 4 where both the ring and patch are introduced. 
The results are presented in Figure 5 for three alternative scenarios: promotion and 
price reduction separately and then in combination.  
 
While the predicted increases in market share for the vaginal ring are large in relative 
terms, the actual shares remain small. When the ring is promoted and has a substantial 
price discount its market share is still only 6.7% compared to the predicted share for 
the patch of 12.6%. Because the induced increase in the demand for the ring is small 
in magnitude, the impact on the other market shares are also small in magnitude but 
proportionately the largest declines, across each scenario, are seen for the injection 





Our results have provided a clear picture of what women value when making choices 
between alternative contraceptive products.  In our econometric modeling we also 
stressed the need to specify a model allowing flexible substitution patterns between 
products. This was important because there are likely to be very different patterns of 
substitutability across existing products but also because a key objective of our work 
was to simulate the introduction of the hormonal patch and vaginal ring into the 
current Australian market. As expected these substitution patterns were very different 
from the proportional substitution patterns that would arise using say conditional logit 
models. One distinctive finding from these simulations was the lack of sensitivity of 
the market shares of the new products across scenarios whether they were introduced 
separately or together. This is clear evidence that the ring and patch appeal to different 
segments of the market. The other important finding was the clear preference for the 
patch over the ring even when the latter was promoted and made cheaper.    
 
The current work has concentrated on the preferences of women but as with many 
health-related decisions, doctors can exert considerable influence on the decisions of 
patients through their recommendations. Doctor recommendations have been included 
amongst our set of attributes and hence have been exogenously given. It is of interest 
to investigate whether the preferences of doctors align with those of women and how 
doctors decide on what types of contraceptive products to discuss with women. These 





Table 1: Attributes and levels of the contraceptive product options 
Attribute  Level 
product 0  Combined Pill 
 1  Mini pill 
 2  Depot Injection 
 3  Implant 
 4  Intra-uterine hormonal device 
 5  Patch 
 6  Ring 
 7  IUD 
   Generic attributes   
effect on acne 0  This product has no effect on acne symptoms 
 1  In some women, this product improves acne symptoms 
 2  In some women this product worsens acne symptoms 
effect on weight 0  This method has no effect on weight 
 1  Some women using this method may lose up to 1 kg in weight 
 2  Some women using this method may gain up to 1 kg in weight 
 3  Some women using this method may lose up to 3 kg in weight 
 4  Some women may gain  up to 3 kg in weight 
Doctor's recommendation 0  Your doctor recommends this product for you 
 1  Your doctor says this may not be a good method for you 
 2  Your doctor says this is a suitable method for you 
 3  Your doctor makes no recommendation 
cost 0  $1 per month 
 1  $7 per month 
 2  $20 per month 
 3  $60 per month 
effect on bleeding 0 Most women using this method experience no periods 
 1 Most women using this method experience irregular bleeding 
 2 Most women using this method experience light periods with less pain 
 3 
Most women using this method experience light periods with no change 
in pain 
 4 
Most women using this method experience light periods with increased 
pain 
 5 Most women using this method experience heavy periods with less pain 
 6 
Most women using this method experience heavy periods with no change 
in pain 
 7 
Most women using this method experience heavy periods with increased 
pain 
   Alternative specific attributes (nested) 
frequency of administration pill 0  1 per day 
 1  1 per day within interval 
 2  1 per day at same time  
frequency of administration  0  Once a month 
injection, patch and ring 1  Once every 3 months 
 2  Once every six months 
frequency of administration IUD  0  Once a  year 
implant 1  Once every 3 years 
 2  Once every 5 years 
contraceptive effectiveness implant,  0  1/1000 women using this product get pregnant in a 12 month period 
injection and IUD 1  1/500 women using this product get pregnant in a 12 month period 
 2  1/100 women using this product get pregnant in a 12 month period 
contraceptive effectiveness pill,  0 1/100 women using this product get pregnant in a 12 month period 
patch and ring 1  5/100 women using this product get pregnant in a 12 month period 





Table 2: Sample characteristics:  
Total sample and basic information treatment* 
 
 Total sample Condition 1: 
Basic information 
Sample size 528 171 
 % % 
Age (years)   
18-19 5.13 5.29 
20-24 22.05 25.29 
25-29 19.39 21.76 
30-34 19.20 17.06 
35-39 17.68 13.53 
40-44 11.60 11.76 
45-49 4.94 5.29 
   
Household Income   
No income 2.29 2.92 
$1-$149 0.19 0.58 
$150-$249 2.48 1.75 
$250-$399 4.00 4.09 
$400 - $599 6.86 9.94 
$600 - $799 8.95 8.19 
$800 - $999 9.90 8.19 
$1000 - $1299 15.43 12.87 
$1300 - $1599 17.52 20.47 
$1600 - $1999 14.48 13.45 
> $2000 17.90 17.54 
   
Employment   
Full time 43.81 44.97 







   
Smoking status   
Regular 21.48 20.7 
Occasional 5.32 7.10 
Non-smoker 73.19 71.35 
   
Current Contraception   
Oral pill 50.57 57.89 
Condoms 52.08 53.80 
Emergency 6.06 5.85 
Implant 5.49 4.68 
Vaginal Ring 0.95 0.00 
IUD 2.65 1.75 
Injection 4.17 4.09 
No effective 14.39 14.62 
*There were a small number of missing observations in the total sample. Sample statistics 






Table 3: Patterns of contraceptive use in Australia* 
 All Using  contraception 
Using prescribed 
contraceptive 
Sample size  3044 1847  929 
 % % % 
Oral 25.3 41.3 82.1 
Condom 19.3 31.5   
Tubal/hysterectomy 8.4 13.8  
Vasectomy 8.8 14.5  
Intra-uterine device 1.4 2.3 4.6 
Injectable 1.8 2.9 5.8 
Implant 2.3 3.8 7.6 
Withdrawal 2.1 3.5  
Safe period method 1.4 2.2  
Other 1.0 1.6  
* Source: HILDA 2005 
 
 
Table 4: Comparison of model fit* 
 MNL MXL G-MNL-A G-MNL-B G-MNL-C 
      
Random scale No No Yes Yes Yes 
Random ASCs No correlated No uncorrelated correlated 
      
Log-likelihood -5393.3 -4932.5 -5260.9 -5030.6 -4836.3 
Parameters 55 83 56 63 84 
AIC 10896 10031 10633 10187 9840 
BIC 11259 10579 11003 10603 10395 
Pseudo-R2* 0.093 0.170 0.115 0.154 0.186 
*Null model for comparison is the product intercepts only MNL model with log likelihood = -5942.94. 








Table 5: G-MNL-C estimation results 
  Coefficient Std. Err. p-value 
Random Product Intercepts     
combined pill Mean 0.645 0.536 0.23 
 Std Deviation 2.130 0.221 0.00 
minipill Mean 0.347 0.528 0.51 
 Std Deviation 2.112 0.223 0.00 
injection Mean 0.910 0.451 0.04 
 Std Deviation 0.964 0.225 0.00 
implant Mean 0.363 0.350 0.30 
 Std Deviation 0.854 0.228 0.00 
hormonal IUD Mean 0.175 0.290 0.55 
 Std Deviation 0.355 0.242 0.14 
Patch Mean 0.463 0.520 0.37 
 Std Deviation 1.685 0.222 0.00 
ring Mean -0.543 0.541 0.32 
 Std Deviation 1.278 0.316 0.00 
Fixed parameter attributes    
effect on acne    
  improves acne symptoms 0.030 0.070 0.67 
  worsens acne symptoms -0.367 0.059 0.00 
effect on weight    
  lose up to 1 kg in weight -0.064 0.076 0.40 
  gain up to 1 kg in weight -0.304 0.079 0.00 
  lose up to 3 kg in weight 0.062 0.086 0.47 
  gain  up to 3 kg in weight -0.509 0.094 0.00 
frequency of administration    
 1 per day within interval -0.207 0.154 0.18 
 1 per day at same time  -0.135 0.163 0.41 
 Once every 3 months 0.003 0.125 0.98 
 Once every six months 0.217 0.132 0.10 
 Once every 3 years 0.062 0.129 0.63 
 Once every 5 years 0.061 0.121 0.62 
contraceptive effectiveness    
 1/500 women get pregnant in a 12 month period -0.205 0.091 0.02 
 1/100 women get pregnant in a 12 month period -0.534 0.115 0.00 
 5/100 women get pregnant in a 12 month period -0.336 0.098 0.00 
 10/100 women get pregnant in a 12 month period -0.597 0.109 0.00 
Doctor's recommendation    
  may not be a good method for you -0.805 0.102 0.00 
  suitable method for you -0.197 0.095 0.04 
  no recommendation -0.428 0.087 0.00 
linear cost ($100’s) -1.978 0.201 0.00 
effect on bleeding    
  irregular bleeding -0.743 0.117 0.00 
   light periods with less pain 0.023 0.102 0.82 
 light periods with no change in pain -0.007 0.101 0.95 
  light periods with increased pain -0.635 0.108 0.00 
  heavy periods with less pain -0.540 0.115 0.00 
 heavy periods with no change in pain -0.631 0.095 0.00 
  heavy periods with increased pain -1.378 0.160 0.00 
Covariates    
Household weekly income midpoints ($1000’s)    
Effect on combined pill -0.474 0.339 0.16 
Effect on minipill -0.393 0.327 0.23 
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Effect on injection -0.460 0.237 0.05 
Effect on implant -0.191 0.187 0.31 
Effect on hormonal IUD -0.166 0.179 0.35 
Effect on patch -0.126 0.321 0.69 
Effect on ring -0.111 0.300 0.71 
Current method = other than pill    
Effect on combined pill -1.219 1.056 0.25 
Effect on minipill -1.254 1.027 0.22 
Effect on injection 0.092 0.695 0.90 
Effect on implant 0.224 0.601 0.71 
Effect on hormonal IUD -0.130 0.664 0.85 
Effect on patch -1.466 0.874 0.09 
Effect on ring -0.950 0.902 0.29 
Current method = pill only    
Effect on combined pill 0.314 0.446 0.48 
Effect on minipill 0.443 0.428 0.30 
Effect on injection 0.000 0.358 1.00 
Effect on implant 0.181 0.317 0.57 
Effect on hormonal IUD 0.166 0.275 0.55 
Effect on patch -0.423 0.420 0.31 
Effect on ring -0.091 0.432 0.83 
 
Scale heterogeneity (τ) 0.781 0.085 0.00 
 
Log-likelihood -4836.3   
Number of observations 5472   





Table 6: Calibration results 













Combined Pill 0.64 0.18 5.03 0.37 0.41 
Mini pill 0.35 0.16 4.84 0.37 0.41 
Injection 0.91 0.23 1.49 0.07 0.06 
Implant 0.36 0.12 2.53 0.09 0.08 
Hormonal IUD 0.18 0.21 -2.07 0.07 0.02 
IUD 0.00 0.12 0.00 0.03 0.02 
* Based on HILDA where rates for the oral pill have been allocated equally between the combined pill 
and the minipill. Similarly the HILDA rates for the intra-uterine device have been equally allocated to 




Figure 1: Example of a choice set 
 
Compare the characteristics of options A B & C then answer the questions below  
 
A B C
Product Mini Pill Intra-uterine Hormonal Device Mini Pill
Effect on Acne In some women, this product 
improves acne symptoms
In some women this product 
worsens acne symptoms
In some women this product 
worsens acne symptoms
Effect on Weight This product has no ef fect on 
weight
Some women using this 
product may gain up to 1 kg in 
weight
Some women using this 
product may lose up to 1 kg in 
weight
Frequency of Administration 1 per day Once every 5 years 1 per day within interval
Contraceptive Effectiveness 
10/100 women using this 
product get pregnant in a 12 
mth period
1/500 women using this 
product get pregnant in a 12 
mth period
1/100 women using this 
product get pregnant in a 12 
mth period
Doctor’s Recommendation Your doctor says this may not 
be a good method for you
Your doctor makes no 
recommendation
Your doctor says this is a 
suitable method for you
Effect on Periods
Most women using this 
method experience heavy 
periods with less pain
Most women using this 
method experience heavy 
periods with less pain
Most women using this 
method experience heavy 
periods with less pain
Cost $7 per month $20 per month $20 per month
Of the options presented 
above, which do you like the 
most?
Of the options presented 
above, which do you like the 
least?
 
If you had to choose from the option above that you like the most, or your current 





































Figure 3: Relative impact of contraceptive attributes on women’s 
choices: Marginal WTP relative to base case ($A) 
 








































Current Add ring & patch Add patch only Add ring only
 




Figure 5: Forecasts of market shares after introduction of new products 
























Add ring & patch Promotion Price reduction Both  
* The promotion involves a positive GP recommendation for the ring and the price reduction is 
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